Search hospitals > Maryland > Columbia
Maryland Oncology Hematology, PA
Claim this profileColumbia, Maryland 21044
Global Leader in Breast Cancer
Global Leader in Non-Small Cell Lung Cancer
Conducts research for Lung Cancer
Conducts research for Prostatic Neoplasm
Conducts research for Prostate Cancer
69 reported clinical trials
5 medical researchers
Summary
Maryland Oncology Hematology, PA is a medical facility located in Columbia, Maryland. This center is recognized for care of Breast Cancer, Non-Small Cell Lung Cancer, Lung Cancer, Prostatic Neoplasm, Prostate Cancer and other specialties. Maryland Oncology Hematology, PA is involved with conducting 69 clinical trials across 115 conditions. There are 5 research doctors associated with this hospital, such as Kashif Ali, Mohit Narang, MD, Yousuf Gaffar, MD, and Cheryl A Aylesworth.Area of expertise
1Breast Cancer
Global LeaderStage IV
HER2 negative
Stage III
2Non-Small Cell Lung Cancer
Global LeaderStage IV
RET
Stage III
Top PIs
Kashif AliGSK Investigational Site2 years of reported clinical research
Studies Obesity
Studies Childhood Obesity
11 reported clinical trials
18 drugs studied
Mohit Narang, MDMaryland Oncology Hematology, P.A4 years of reported clinical research
Studies Esophageal Cancer
Studies Pancreatic Adenocarcinoma
4 reported clinical trials
12 drugs studied
Yousuf Gaffar, MDMaryland Oncology Hematology, P.A.4 years of reported clinical research
Studies Colorectal Cancer
Studies Colon Cancer
3 reported clinical trials
8 drugs studied
Cheryl A AylesworthMaryland Oncology Hematology, P.A.4 years of reported clinical research
Studies Ovarian Cancer
Studies Cervical Cancer
3 reported clinical trials
9 drugs studied
Clinical Trials running at Maryland Oncology Hematology, PA
Breast Cancer
Multiple Myeloma
Melanoma
Plasma Cell Neoplasm
Myelofibrosis
Myelodysplastic Syndrome
Myelodysplastic/Myeloproliferative Neoplasms
Relapse
Prostatic Neoplasm
Prostate Cancer
Elacestrant
for Breast Cancer
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Recruiting2 awards Phase 33 criteria
Tucatinib + Doxil
for Breast Cancer
This clinical trial is evaluating tucatinib in combination with Doxil in participants with human epidermal growth factor 2 positive (HER2+) locally advanced or metastatic breast cancer. The main goals of this study are to: * Learn how well the combination of tucatinib and Doxil works * Learn more about the side effects of the combination of tucatinib and Doxil
Recruiting1 award Phase 213 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Maryland Oncology Hematology, PA?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.